A few weeks ago, I noticed an excellent article by Adam Feuerstein, Senior Columnist at TheStreet.com called Putting a Value on Provenge describing what went into the evaluation of a single biotech company when analyzing the impact of an approval on stock price. I found it extremely interesting to look at all the variables that are involved.
I asked Adam if he would be interested in chatting about that in a podcast and he kindly agreed.
We covered the objective and subjective factors that go into looking at a company as a new product is coming out. We also discussed some of the factors that lead to a stock price that goes up after an announcement of an approvable letter versus one that tanks. And he shared thoughts on challenges for the coming year.
I hope you enjoy and many thanks to Adam Feuerstein at TheStreet.com